MAGERS Extension, Canada

Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties
Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group
Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Registration Status: Pending

Objective: This study will evaluate the utility of intensive biochemical and genomic screening for inborn errors of metabolism (IEMs) and other genetic disorders in patients admitted to the BC Psychosis Program (BCPP), and outpatients through the UBC Neuropsychiatry Program, Delta Hospital Neuropsychiatry Outpost, and psychosis-specific outpatient programs in the Health Authorities with treatment-resistant psychosis (TRP), in informing clinical diagnosis, pathophysiology, and prognosis. Epigenetic analyses will also be performed when data is available from WGS. Genomic biomarkers of clozapine response, tolerance, and superior efficacy over other antipsychotics will be sought. The latter will be done strictly naturalistically, as clozapine is standard-of-care for patients with TRP.

Registered Biobank Name	MAGERS Extension
Biobank Leader	Mohadeseh Gharib Pour
Country	Canada
Email for biobank inquiries	magers.ra@ubc.ca
Principal Investigator	Dr. Robert Stowe
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Biospecimen Collected: